|
Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
The difference between SGLT2 and DPP-4 inhibitors on glucose fluctuation in patients with type 2 diabetes
This item is licensed under:Creative Commons Attribution 3.0 Unported
| Title: | The difference between SGLT2 and DPP-4 inhibitors on glucose fluctuation in patients with type 2 diabetes |
| Authors: | Nomoto, Hiroshi Browse this author | | Miyoshi, Hideaki Browse this author →KAKEN DB |
| Keywords: | Glucose fluctuation | | Dipeptidyl peptidase-4 inhibitors | | Sodium-glucose co-transporter 2 inhibitors | | Type 2 diabetes mellitus |
| Issue Date: | 2017 |
| Publisher: | Insight Medical Publishing |
| Journal Title: | British Journal of Research |
| Volume: | 4 |
| Issue: | 3 |
| Start Page: | 21 |
| Publisher DOI: | 10.21767/2394-3718.100021 |
| Abstract: | Various oral and parental hypoglycemic agents have been developed to achieve adequate glycemic control in patients with type 2 diabetes mellitus. Because of the relatively high prevalence of cardiovascular events in this patient population, it is also necessary to minimize glucose fluctuation to prevent atherosclerotic disease. Two different types of hypoglycemic agents, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter 2 inhibitors, appear to control glucose variability to a similar extent, but their efficacy might depend somewhat on the patient's background. To clarify which type of drug is more appropriate for use in a given patient, further investigation is needed. |
| Rights: | https://creativecommons.org/licenses/by/3.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/67257 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 三好 秀明
|
